Pfizer Challenges GLP-1 Duopoly with Monthly Weight-Loss Injectable

Pfizer is positioning itself to break the current duopoly in the anti-obesity medication (AOM) market held by Eli Lilly and Novo Nordisk. The pharmaceutical giant is developing PF-08653944, a GLP-1 receptor agonist that could offer a significant convenience advantage over existing therapies. While Novo Nordisk's Wegovy and Eli Lilly's Zepbound have defined the current landscape, their weekly injection requirements have led to high discontinuation rates, with up to two-thirds of users stopping treatment within a year. Pfizer's candidate aims to shift this paradigm by requiring only one subcutaneous injection per month to achieve comparable results. In Phase 2b trials, PF-08653944 demonstrated weight loss between 10% and 12% by week 28 of a low-to-medium dose regimen. While these efficacy results are largely in line with existing GLP-1 alternatives, the monthly cadence could lower total costs and improve patient adherence. The entry of a third major player is expected to intensify an existing price war. Novo Nordisk has already projected a 5% to 13% decline in top and bottom lines this year due to weakness in its weight-loss business. Meanwhile, Eli Lilly's Zepbound saw revenue surge from $4.9 billion to $13.5 billion last year, though growth rates began to decelerate by the fourth quarter. With the anti-obesity market projected to grow at a compound annual rate of nearly 25% through 2035, the competition for market share is intensifying. Pfizer's potential entry threatens the pricing power of the first movers as the industry shifts toward more affordable and convenient delivery methods.